No Data
No Data
We Think NewAmsterdam Pharma (NASDAQ:NAMS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
Express News | NewAmsterdam Pharma Company NV: Patent Extends Obicetrapib's Ip Protection and Exclusivity Until July 2043
Express News | NewAmsterdam Pharma Company NV: Issuance of Composition of Matter Patent for Obicetrapib by United States Patent and Trademark Office
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmst
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital analyst Leonid Timashev maintains $NewAmsterdam Pharma(NAMS.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 33.3
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients